NVAX Novavax Inc

Price (delayed)

$8.78

Market cap

$1.43B

P/E Ratio

3.38

Dividend/share

N/A

EPS

$2.6

Enterprise value

$1.39B

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III ...

Highlights
Novavax's equity has surged by 150% QoQ and by 109% YoY
NVAX's quick ratio has surged by 132% year-on-year and by 17% since the previous quarter
Novavax's EPS has surged by 197% YoY but it has decreased by 14% QoQ
NVAX's gross profit has soared by 52% YoY but it is down by 13% QoQ
Novavax's net income has decreased by 12% from the previous quarter

Key stats

What are the main financial stats of NVAX
Market
Shares outstanding
162.42M
Market cap
$1.43B
Enterprise value
$1.39B
Valuations
Price to earnings (P/E)
3.38
Price to book (P/B)
37.8
Price to sales (P/S)
1.32
EV/EBIT
3.06
EV/EBITDA
2.8
EV/Sales
1.29
Earnings
Revenue
$1.08B
Gross profit
$951.99M
Operating income
$351.49M
Net income
$422.82M
EBIT
$454.45M
EBITDA
$495.57M
Free cash flow
-$637.33M
Per share
EPS
$2.6
EPS diluted
$2.6
Free cash flow per share
-$3.93
Book value per share
$0.23
Revenue per share
$6.66
TBVPS
$7.55
Balance sheet
Total assets
$1.34B
Total liabilities
$1.3B
Debt
$228.49M
Equity
$37.63M
Working capital
$530.37M
Liquidity
Debt to equity
6.07
Current ratio
2.36
Quick ratio
2.18
Net debt/EBITDA
-0.07
Margins
EBITDA margin
45.9%
Gross margin
88.3%
Net margin
39.2%
Operating margin
32.6%
Efficiency
Return on assets
28.7%
Return on equity
N/A
Return on invested capital
117%
Return on capital employed
48%
Return on sales
42.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVAX stock price

How has the Novavax stock price performed over time
Intraday
15.83%
1 week
32.03%
1 month
32.83%
1 year
-18.02%
YTD
9.2%
QTD
39.37%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$1.08B
Gross profit
$951.99M
Operating income
$351.49M
Net income
$422.82M
Gross margin
88.3%
Net margin
39.2%
NVAX's gross profit has soared by 52% YoY but it is down by 13% QoQ
NVAX's gross margin is up by 39% year-on-year
Novavax's operating income has decreased by 15% from the previous quarter
The revenue has contracted by 14% from the previous quarter but it has grown by 9% YoY

Price vs fundamentals

How does NVAX's price correlate with its fundamentals

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
3.38
P/B
37.8
P/S
1.32
EV/EBIT
3.06
EV/EBITDA
2.8
EV/Sales
1.29
Novavax's EPS has surged by 197% YoY but it has decreased by 14% QoQ
Novavax's equity has surged by 150% QoQ and by 109% YoY
NVAX's P/S is 77% below its 5-year quarterly average of 5.7 and 12% below its last 4 quarters average of 1.5
The revenue has contracted by 14% from the previous quarter but it has grown by 9% YoY

Efficiency

How efficient is Novavax business performance
The ROIC has plunged by 52% from the previous quarter
NVAX's return on assets is down by 4.3% since the previous quarter
Novavax's return on sales has increased by 3.4% QoQ

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 2.9% higher than its total liabilities
NVAX's quick ratio has surged by 132% year-on-year and by 17% since the previous quarter
The current ratio has surged by 127% year-on-year and by 15% since the previous quarter
Novavax's equity has surged by 150% QoQ and by 109% YoY
Novavax's debt has decreased by 2% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.